Vicore Pharma Holding AB
VCRE | NASDAQ
$9.80
-$0.40 (-3.92%)
At close: Oct 30, 2026, 4:00 PM ET
$9.61
-$0.19 (-1.94%)
After-hours:
Oct 30, 2026, 4:34 PM ET
Company Profile
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Key Executives
| Name | Position |
|---|---|
| Ahmed S. Mousa | Chief Executive Officer |
| Hans Jeppsson | Chief Financial Officer |
| Helen Barker | Chief Technology Officer |
| Mikael Nygård | Chief Operating Officer |
| Bernt van den Blink | Chief Medical Officer |
| Jason Hoffman | VP & Head of Human Resources |
| Jimmie Hofman | Chief Business Officer |
| Johanna Grans | Head of Non-Clinical Development |
| Karam Hijji | General Counsel |
| Lene Eskildsen | Head of Quality Assurance |
| Megan Richards | VP of Investor Relations, Communications & Portfolio Strategy |
| Nina Carlen | Chief Administrative Officer |
| Rob Slack | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 6-K | Filing |
| Aug 21, 2026 | S-8 | Filing |
| Aug 21, 2026 | 6-K | Filing |
| Jul 06, 2026 | 6-K | Filing |
| Jun 30, 2026 | SEC STAFF ACTION | Filing |
| Jun 30, 2026 | CERT | Filing |
| Jun 09, 2026 | 20FR12B/A | [Amend] Filing |
| May 22, 2026 | 20FR12B | Filing |
| Apr 17, 2026 | DRS | Filing |
Vicore Pharma Holding AB
| Country | Sweden |
| IPO Date | Jul 2, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Ahmed Mousa |
Stock Details
| Ticker Symbol | VCRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002124403 |
| CUSIP Number | 92581R104 |
| ISIN Number | US92581R1041 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove VCRE